Firm will utilize the MASStermind and MASSterclass technologies.

Pronota signed an agreement allowing its MASStermind® platform for protein biomarker discovery and its MASSterclass™ biomarker verification platform to be used by Molecuence. The company will leverage the technologies to discover and validate protein biomarkers in stroke.

Pronota develops protein biomarker diagnostics using a platform that mines for low-abundance protein biomarkers in blood and other tissues. MASSterclass™ verifies biomarkers identified by MASStermind® without the use of antibody-based assays, according to the company.

Promota’s pipeline consists of four programs focused on diagnostic blood tests for cardiorenal disease, pre-eclampsia, sepsis, and ovarian cancer. Founded in late 2004, Pronota announced the raising of a series B financing round of €7.9 million (about $10.8 million) last year.

Moleculence, a wholly owned subsidiary of Mitsubishi Chemical, focuses on R&D of advanced biomarkers that can enable diagnosis and prediction of cardiovascular and metabolic diseases. Molecuence works with researchers at Kyushu University Faculty of Medicine and Hisayama Research Institute for Lifestyle Diseases.

Previous articleIntegenX Licenses Caliper Microfluidics for Use in DNA Profiling Identification System
Next articleNovartis to Assess Quanterix’ Single Molecule Array Platform for Diagnostic Use